<!DOCTYPE html>
<html lang="en-US">
<head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width initial-scale=1.0" />
    <title>VASCEPA (icosapent ethyl) - Dosing and Administration</title>
    <meta name="description" content="VASCEPA is dosed 4 g/d—2 capsules, twice daily, with food. VASCEPA is an ethyl ester of EPA that reaches steady state in 14 days.">
    <meta name="keywords" content="VASCEPA, dosing, capsules, pharmacokinetics, absorption, steady state, time to Cmax, distribution, EPA plasma levels, metabolism, excretion">
    <link rel="stylesheet" type="text/css" href="includes/style.css">
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.3/jquery.min.js"></script>
    <script src="includes/main.js"></script>
    <script type="text/javascript">
        if(navigator.userAgent.match(/iPad/i)) {
            viewport = document.querySelector("meta[name=viewport]");
            viewport.setAttribute('content', 'width=960');
        }
    </script>
    <script src="//use.typekit.net/kfd3zyz.js"></script>
    <script>try{Typekit.load({ async: true });}catch(e){}</script>    <script>try{Typekit.load();}catch(e){}</script>
    <script>
        (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
        (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
        m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
        })(window,document,'script','//www.google-analytics.com/analytics.js','ga');
        ga('create', 'UA-60954107-1', 'auto');
        ga('send', 'pageview');
        
    </script>
    <script src="http://crypto-js.googlecode.com/svn/tags/3.1.2/build/rollups/sha1.js"></script>
    <script src="http://services.revhealthbackend.com/js/urlPassword.js"></script>
</head>
    
<body>
    <div id="wrapper">
        <div id="currentpg" data-current="dosing"></div>
        <div id="top-content"></div>
        <div id="content" class="content-wrap">
            <div id="page-content">
                <div class="center-col no-side">
                    <div class="page-text">
                        <h1>VASCEPA Dosing and Administration<sup>1</sup></h1>
                        <p>
                            <img class="alignleft" title="image of VASCEPA bottle, capsules, and Rx pad" src="includes/uploads/VASCEPA-product-shot-Rx.png" alt="image of VASCEPA bottle, capsules, and Rx pad" width="364" height="252">
                            The daily dose of VASCEPA (icosapent ethyl) is 4&nbsp;g/d taken as 2 capsules twice daily with food.
                        </p>
                        <p>Patients should be advised to swallow VASCEPA capsules whole. They should not break open, crush, dissolve, or chew VASCEPA. Health care professionals should assess lipid levels before initiating therapy and identify other causes (eg, diabetes mellitus, hypothyroidism, alcohol intake, or medications) of high TG levels and manage as appropriate. Patients should also be following an appropriate lipid-lowering diet and exercise regimen before and during treatment with VASCEPA.</p>
                        <div class="clear">
                            <h5>VASCEPA is an ethyl ester of EPA that achieves steady state in 14 days<sup>1-3</sup></h5>
                        </div>
                        <img class="aligncenter" style="width: 100%;" src="includes/uploads/Table-header-BG-gradient.png" alt="Table-header-BG-gradient" width="564" height="21">
                        <table>
                            <tbody>
                                <tr>
                                    <td>Absorption</td>
                                    <td>De-esterified; active metabolite EPA absorbed in small intestine.</td>
                                </tr>
                                <tr>
                                    <td>Time to C<sub>max</sub></td>
                                    <td>5 hours</td>
                                </tr>
                                <tr>
                                    <td>Distribution</td>
                                    <td>The majority of EPA circulating in plasma is incorporated in phospholipids, TGs, and cholesterol esters, and &lt;1% is present as the unesterified fatty acid. Greater than 99% of unesterified EPA is bound to plasma proteins.</td>
                                </tr>
                                <tr>
                                    <td>Time to steady state</td>
                                    <td>14 days</td>
                                </tr>
                                <!-- <tr>
                                    <td>Increase in EPA plasma levels</td>
                                    <td>5 times greater from baseline to the end of the 12-week study (baseline, 61.2 μg/mL; end of treatment, 326.7 &micro;g/mL).</td>
                                </tr> -->
                                <tr>
                                    <td>Metabolism</td>
                                    <td>EPA is mainly metabolized by the liver via beta-oxidation similar to dietary fatty acids. Beta-oxidation splits the long carbon chain of EPA into acetyl-coenzyme A, which is converted into energy via the Krebs cycle. Cytochrome P450&ndash;mediated metabolism is a minor pathway of elimination of EPA.</td>
                                </tr>
                                <tr>
                                    <td>Excretion</td>
                                    <td>The total plasma clearance of EPA at steady state is 684 mL/h. The plasma elimination half-life (t<sub>1/2</sub>) of EPA is approximately 89 hours. VASCEPA does not undergo renal excretion.</td>
                                </tr>
                            </tbody>
                        </table>
                        <p><span style="font-size: 12px;">C<sub>max</sub>, maximum plasma concentraion; EPA, elcosapentaenoic acid; TG, triglyceride.</span></p>
                    </div>
                    <div class="load-disclaimer"></div>
                    <div class="references">
                        <strong>References: 1.</strong> VASCEPA [package insert]. Bedminster, NJ; Amarin Pharma Inc.; 2015. <strong>2.</strong> Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. <em>Postgrad Med.</em> 2014;126(7):7-18. <strong>3.</strong> Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects. <em>Clin Pharmacol Drug Dev.</em> 2013;3(2):101-108.
                    </div>
                </div>
                <div class="page-sidebar">
                    <div class="load-callout"></div>
                    <div class="load-disclaimer"></div>
                </div>
            </div>
        </div>
        <div id="footer"></div>
    </div>
</body>
</html>